Urothelial Carcinoma Clinical Trials

75 recruiting

Urothelial Carcinoma Trials at a Glance

165 actively recruiting trials for urothelial carcinoma are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 2 with 68 trials, with the heaviest enrollment activity in New York, Chicago, and Houston. Lead sponsors running urothelial carcinoma studies include National Cancer Institute (NCI), Mayo Clinic, and IRCCS San Raffaele.

Browse urothelial carcinoma trials by phase

Treatments under study

About Urothelial Carcinoma Clinical Trials

Looking for clinical trials for Urothelial Carcinoma? There are currently 75 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Urothelial Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Urothelial Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 165 trials

Recruiting
Phase 2Phase 3

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Renal Pelvis and Ureter Urothelial Carcinoma
National Cancer Institute (NCI)249 enrolled258 locationsNCT04628767
Recruiting
Phase 2

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled134 locationsNCT07061964
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2Phase 3

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled493 locationsNCT05987241
Recruiting
Phase 2

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Urothelial CarcinomaAdvanced Urothelial CarcinomaUrothelial Carcinoma Recurrent
Sun Yat-sen University96 enrolled6 locationsNCT07241793
Recruiting
Phase 3

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI)320 enrolled129 locationsNCT06524544
Recruiting
Phase 1Phase 2

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Urothelial Carcinoma
Merck Sharp & Dohme LLC48 enrolled28 locationsNCT05562830
Recruiting
Phase 3

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Urothelial CarcinomaUpper Urinary Tract Urothelial Carcinoma
UroGen Pharma Ltd.70 enrolled52 locationsNCT06774131
Recruiting
Phase 2

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Urothelial Carcinoma
University of California, Irvine23 enrolled1 locationNCT06682728
Recruiting
Not Applicable

Bladder Cancer Screening Trial

Urothelial CarcinomaBladder CancerSmoking Cessation+1 more
University of Texas Southwestern Medical Center1,000 enrolled1 locationNCT05646485
Recruiting
Phase 2

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled124 locationsNCT06770582
Recruiting
Not Applicable

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Bladder CancerOligometastasisUrothelial Carcinoma (UC)
Istituto Clinico Humanitas44 enrolled1 locationNCT07413523
Recruiting
Phase 1

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma+1 more
Emory University32 enrolled1 locationNCT04878029
Recruiting
Not Applicable

Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity

Urothelial Carcinoma Bladder
Ludwig-Maximilians - University of Munich146 enrolled1 locationNCT06806059
Recruiting

Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria

Urothelial Carcinoma
Pacific Edge Limited1,000 enrolled4 locationsNCT05889195
Recruiting
Phase 2

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer372 enrolled223 locationsNCT04879329
Recruiting
Phase 1

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Urothelial Carcinoma Bladder
Aktis Oncology, Inc.150 enrolled9 locationsNCT07020117
Recruiting
Phase 1

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Urothelial CarcinomaRenal Cell CarcinomaCastration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC60 enrolled4 locationsNCT06966024
Recruiting
Phase 1Phase 2

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Urothelial CarcinomaUrothelial CancerAdvanced/Metastatic Urothelial Cancer
Pfizer132 enrolled40 locationsNCT07421700
Recruiting
Phase 1

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Advanced Urothelial CarcinomaOral Drug AdministrationOpen Label
Flare Therapeutics Inc.120 enrolled12 locationsNCT05929235